Skip to main content
Log in

The relationship between the pharmacokinetics of amrinone in the marmoset and platelet effects

  • Original papers
  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

The pharmacokinetic characteristics of amrinone have been studied in six female marmosets following oral administration of 1, 12.5, 25, 50 and 75 mg.kg−1 and an intravenous dose of lmg.kg−1. The mean plasma AUG)0 was determined at each dose level; the values obtained were 2.5, 18.7, 33.9, 103 and 312 μ.h.ml−1 for the oral doses of 1. 12.5, 25, 50 and 75 mg.kg−1 respectively and 1.9 μ.h.ml−1 for the intravenous dose of lmg.kg−1 Mean maximum observed plasma concentrations were 0.6, 7.1, 11.7, 23.7 and 40.0 μg.ml−1 respectively following oral doses. Over the range 1 to 50 mg.kg0 the AUCooe was linear; at 75 mg.kg−1 the AUCo0 8 was disproportionately greater. Elimination appeared to be first order over the dose range 1 to 50 mg.kg−1 and the 11/2 in the marmoset was approximately 1 to 3 hours over this dose range. The plasma levels achieved arc discussed in relation to the observed effects on the platelet population in this species following chronic administration at high dose levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Ward A., Brogden R.N., Heel R.C., Speight T.M., Avery G.S. (1983): Amrinone: a preliminary review of its pharmacological properties and therapeutic use. Drugs. 26.468–502.

    Article  CAS  PubMed  Google Scholar 

  2. Baker J.F.. Chalecki B.W., Benziger D.P., OMelia P.E., Clemens S.D., Edelson J. (1982): Metabolism of amrinone in animals. Drug Metab. Dispos., 10.168–172.

    CAS  PubMed  Google Scholar 

  3. Park G.B., Kersher R.P., Angellotti J., Williams R.L., Benct Z.L., Edelson J. (1983): Oral bioavailability and intravenous pharmacokinetics of amrinone in humans. J. Pharm. Sci., 72. 817–819.

    Article  CAS  PubMed  Google Scholar 

  4. Edelson J. Park G.B., Angellotti J., Kershner R.P., Ryan J.J., McMaham F.G. ( 1983): Dose proportionality of amrinone. Clin. Pharmacol. Ther., 34.190–194.

    CAS  PubMed  Google Scholar 

  5. Larijani G.E., Rocci M.L., Newham D.L., Wilson H. (1985): The pharmacokinetics of amrinone at three dose levels in the rabbit. Pharmacol. Commun. Res., 4, 176–177.

    Article  Google Scholar 

  6. Padrini R., Miglioli P.A., Casiglia E., Piovan D., Ferrari M. (1982): Farmacocinetica sperimentale and clinica delTamrinone. Boll. Soc. Ital. Cardiol., 27. 103–106.

    Google Scholar 

  7. Kullberg M.P., Dorrbecker B., Lennon J., Rowe E., Edelson J. (1980): High performance liquid chromatographic analysis of amrinone and its N-acetyl derivative in plasma. Pharmacokinetics of amrinone in the dog. J. Chromatogr., 187. 264–270.

    Article  CAS  PubMed  Google Scholar 

  8. Bason C.T., Pattison A., Howells D.D., Mitcheson J., Bonner F.W. (1986): Platelet population profiles: significance of species variation and drug-induced changes. J. Appl. Toxicol., 6. 437–441.

    Article  Google Scholar 

  9. Eason C.T., Pattison A., Howells D.D., Bonner F.W., Martin J.F. (1988): The effect of amrinone. cyclophosphamide and anti-platelet serum on platelet production in the Gunn rat. J. Appl. Toxicol., In Press.

  10. Kinney E.L., Ballard J.O., Carlin B., Zells R. (1983): Amrinonemedicaled thrombocytopenia. Scand. J. Haematol., 31. 376–380.

    CAS  PubMed  Google Scholar 

  11. Treadway G. (1985): Clinical safety of intravenous amrinone — a review. Am. J. Cardiol.. 56. 39B-40B.

    Article  CAS  PubMed  Google Scholar 

  12. Wilmshurst P.T., AI-Hasan S.A.F., Sample M.J., Hamblin A.S., Kioy P.G., Lucas G.F., Savidge G.F., Webb-Peploe M.M. (1984): The effects of amrinone on platelet count, survival and function in patients with congestive cardiac failure. Br. J. Clin. Pharmacol., 17. 317–324.

    CAS  PubMed  Google Scholar 

  13. Brandt J.T., Miller L., Hermiller J., Unverferth D.V., Leier C.V. (1984): Effect of oral amrinone on platelet function and survival. Clin. Pharmacol. Ther.. 36. 260–264

    CAS  PubMed  Google Scholar 

  14. Eason C.T., Parke D.V., Clark B., Smith D.A. (1982): The mechanism of hepatotoxicity of a chromone carboxylic acid (FPL 52757) in the dog. Xenobiotica. 12.155.

    Article  CAS  PubMed  Google Scholar 

  15. Clarke A.J., Clark B., Eason C.T., Parke. D.V. (1985): An assessment of a toxicological incident in a drug development program and its implications. Regul. Toxicol. Pharmacol., 5. 109–119.

    Article  CAS  PubMed  Google Scholar 

  16. Clark B., Smith D.A. (1984): Pharmacokinetics and toxicity testing. CRC Crit. Rev. Toxicol., 12. 343–385.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eason, C.T., Usansky, J.I., Henry, G.P. et al. The relationship between the pharmacokinetics of amrinone in the marmoset and platelet effects. European Journal of Drug Metabolism and Pharmacokinetics 13, 129–133 (1988). https://doi.org/10.1007/BF03191314

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03191314

Keywords

Navigation